The Impact of Autoantibodies on Outcomes in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analyses of the Phase III ASCEND Trial

Abstract Introduction Clinical practice guidelines recommend autoimmune serological testing in patients newly diagnosed with interstitial lung disease of apparently unknown cause who may have idiopathic pulmonary fibrosis (IPF), in order to exclude connective tissue disease (CTD). Autoantibody posit...

Description complète

Détails bibliographiques

Auteurs principaux:	Tejaswini Kulkarni, Chad A. Newton, Sachin Gupta, Katerina Samara, Elana J. Bernstein
Format:	Artigo
Langue:	Inglês
Publié:	Adis, Springer Healthcare 2024-07-01
Collection:	Pulmonary Therapy
Sujets:	Anti-cyclic citrullinated peptide (anti-CCP) Antinuclear antibody (ANA) Idiopathic pulmonary fibrosis (IPF) Pirfenidone (PF) Rheumatoid factor (RF)
Accès en ligne:	https://doi.org/10.1007/s41030-024-00267-x
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!